Innovation for aging eyes
Tenpoint TherapeuticsTM is advancing innovative therapies for common age-related eye diseases, including presbyopia, cataracts, and geographic atrophy (GA).
Our investigational treatments include:
A small-molecule injectable for cataracts
A regenerative cell replacement therapy for geographic atrophy
Tenpoint TherapeuticsTM partners with eye care professionals to create innovative therapies designed to improve or restore vision and support long-term eye health.
Tenpoint TherapeuticsTM Pipeline
*In clinical trials known as BrimocholTM PF.
NCE=new chemical entity; NDA=New Drug Application.
A multi-targeted approach to treating cataracts
TPT‐161 is an investigational small-molecule therapy designed to delay or prevent cataract surgery.1
It combines an alpha-crystallin chaperone with a reducing agent to:
Address lens hardening and clouding (opacification) Support lens function restoration in aging eyes
TPT-161 mechanism of action
Alpha-crystallins are proteins that help maintain lens transparency by preventing other proteins from clumping. With age, they destabilize—making them key molecular targets in both presbyopia and cataracts.2–5
Alpha-crystallin chaperone: Stabilizes lens proteins and may help reverse lens opacity2–4 Reducing agent: Breaks down protein bonds and may help improve lens clarity and lessen blurred vision1,2,5
Understanding cataracts
Over 1.8 billion people experience presbyopia, and hundreds of millions also develop cataracts. These two conditions are part of dysfunctional lens syndrome (DLS)—a progressive lens condition that begins with loss of accommodation and may result in vision loss or blindness.6–8
Cataracts are caused by
Lens hardening, a natural aging process that affects both cataracts and presbyopia9,10 Misfolded lens proteins and oxidative stress, which increase opacity and lead to glare or blurry vision9,10
Geographic atrophy (GA)
A regenerative cell therapy for treating geographic atrophy
TPT‐005 is an investigational allogenic, regenerative cell therapy for GA.11
Delivered via subretinal injection, it aims to replace lost retinal cells and help restore vision in advanced dry age-related macular degeneration (AMD).
Contains fully differentiated retinal pigment epithelium (RPE) cells derived from human embryonic stem cells (hESC) Developed as a ready-to-use, off-the-shelf injectable therapy
TPT-005 mechanism of action
Geographic atrophy is characterized by irreversible vision loss due to the degeneration of retinal pigment epithelium (RPE) cells and photoreceptors. TPT‐005’s cell-based therapy is designed to restore vision by replacing RPE cells and support photoreceptors.11–13
Cell characteristics: Mimics native RPE physiological function and structure, including pigmentation and biomarkers Cell replacement: Subretinal injection allows cells to engraft and form a functional layer that may restore lost RPE function
Understanding geographic atrophy
GA is a late-stage form of dry AMD that causes irreversible damage to the retina and central vision. It’s a leading cause of vision loss in older adults, affecting 5 million people globally and 1 million in the U.S.12,14
GA is caused by
The death of RPE cells and photoreceptors, which cannot regenerate naturally12,14 Risk factors include age, genetics, and smoking12,14